Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TAK-861 by Takeda Pharmaceutical for Type 1 Narcolepsy (Narcolepsy with Cataplexy): Likelihood of Approval
TAK-861 is under clinical development by Takeda Pharmaceutical and currently in Phase III for Type 1 Narcolepsy (Narcolepsy with Cataplexy)....
TAK-861 by Takeda Pharmaceutical for Narcolepsy: Likelihood of Approval
TAK-861 is under clinical development by Takeda Pharmaceutical and currently in Phase III for Narcolepsy. According to GlobalData, Phase III...
TAK-861 by Takeda Pharmaceutical for Unspecified Neurologic Disorders: Likelihood of Approval
TAK-861 is under clinical development by Takeda Pharmaceutical and currently in Phase I for Unspecified Neurologic Disorders. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Takeda Pharmaceutical's TAK-861?
TAK-861 is a small molecule commercialized by Takeda Pharmaceutical, with a leading Phase III program in Narcolepsy. According to Globaldata,...